Egalet Corporation (NASDAQ:EGLT)’s share price was down 8.7% during mid-day trading on Tuesday . The company traded as low as $1.13 and last traded at $1.16. Approximately 2,302,400 shares traded hands during trading, an increase of 200% from the average daily volume of 766,926 shares. The stock had previously closed at $1.27.
EGLT has been the subject of a number of analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $6.00 target price (down previously from $14.00) on shares of Egalet in a research report on Thursday, August 10th. Guggenheim set a $7.00 target price on shares of Egalet and gave the company a “buy” rating in a research report on Monday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Egalet in a research report on Monday, August 14th. Finally, Gabelli cut shares of Egalet from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $7.10.
The company has a debt-to-equity ratio of -3.43, a current ratio of 2.73 and a quick ratio of 2.68.
Egalet Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.